Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
Akari Therapeutics has been selected to present its novel PH1 antibody drug conjugate (ADC) payload technology at five major oncology, ADC, and healthcare forums throughout September 2026, including events in the United States and China. The company aims to highlight the unique RNA splicing modulator mechanism of its PH1 payload, discuss improving …